Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivastigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 17/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 11/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.86 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivastigmine SCHEMBL6382107 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL13841811 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL1170429 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL2764 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL6382629 | 1.00 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL5803794 | 0.99 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL16568160 | 0.99 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL916695 | 0.99 | ACHE (0.97) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL15519471 | 0.95 | ACHE (0.90) | ACHEBCHEFAAHMARK4MAOA | |
| Rivastigmine SCHEMBL25232361 | 0.93 | ACHE (1.00) | ACHEBCHEFAAHMARK4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025063698-A1 | LAMOTRIGINE AND RIVASTIGMINE COMBINATIONS FOR TREATING NEURODEGENERATIVE DISORDERS | ARIBIO CO. LTD (KR) | 2025-03-27 | — | — | WO | disclosed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | disclosed |
| US-20220160710-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-05-26 | — | — | US | disclosed |